Arizona’s Launch of the NAM Pharma Manufacturing Report

Learn about the biopharmaceutical industry’s footprint in the state of Arizona as we discuss the National Association of Manufacturers’ report:

Ensuring a Health Future: The Impact and Importance of Pharmaceutical Manufacturing.




Shawn DuBravac, PhD, CFA, President, Aviro Institute and New York Times Best Selling Author

Garrick Taylor, EVP, Arizona Chamber of Commerce & Industry

Moderator: Joan Koerber-Walker, president & CEO, Arizona Bioindustry Association (AZBio)

Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines

For Immediate Release:
October 20, 2021
Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations. The agency is amending the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose as follows:Continue reading

Overcoming regulatory challenges to licensing new biotherapeutics

Mayo Clinic’s Symposium on Regenerative Medicine and Surgery will explore the challenges and opportunities of bringing next-generation biotherapeutics to patients. Julie Allickson, Ph.D., the Michael S. and Mary Sue Shannon Director of Mayo Clinic’s Center for Regenerative Medicine, will deliver a keynote presentation addressing regulatory hurdles standing between the billions of dollars invested in regenerative therapies and the people who desperately need new options for healing.

“Last year, there was an almost a $20 billion investment in regenerative biotherapeutics. There’s a significant investment, but not many products being licensed and generating commercialized solutions for patients. What are the challenges, and what are the obstacles,” asks Dr. Allickson. “It requires a partnership to move new discoveries to licensure, engaging industry and working with government agencies to facilitate production of biotherapuetics.” Dr. Allickson is also the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Medicine.Continue reading

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

  • Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.
  • Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs.
  • Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes and advancing personalised healthcare through innovation

Continue reading